New antibody drug enters human testing for Tough-to-Treat blood cancers
NCT ID NCT02530034
Summary
This is a first-in-human study to find a safe dose of an experimental antibody drug called Hu8F4 for patients with advanced blood cancers like leukemia and myelodysplastic syndrome (MDS). The main goals are to check for side effects and see how the body processes the drug. The study will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University
Augusta, Georgia, 30912, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Montefiore Medical Center, Albert Einstein College of Medicine
The Bronx, New York, 10467, United States
Conditions
Explore the condition pages connected to this study.